Compare AbCellera Biologics Inc (ABCL) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Texas Instruments Incorporated — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Texas Instruments Incorporated trades at $304 (market cap $266.93B). The key difference: Texas Instruments Incorporated is far larger — about 113.6× AbCellera Biologics Inc's market cap, and Texas Instruments Incorporated pays a 1.94% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TXN | |
|---|---|---|
Market Cap | $2.35B | $266.93B |
Sector | Health | Technology |
52-Week High | $8.12 | $332.35 |
52-Week Low | $2.78 | $153.33 |
Enterprise Value | $1.99B | $275.88B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Texas Instruments (TXN) trades at $303.50, up 3.56% over 24 hours, with a bullish technical signal and strong profitability metrics including a 29.11% net income margin. Recent Q1 2026 earnings beat expectations, and the company announced a CFO transition with Julie Knecht set to succeed Rafael Lizardi in August 2026. Cash flow trends show improving operational performance, with 2025 operating cash flow at $7.15 billion.
The outlook remains positive with analyst consensus pointing to a $310.95 price target and 47.69% buy ratings. Key risks include elevated valuation ratios like a P/E of 51.88 and rising debt-to-asset ratio, now at 40.61% for 2025. Growth is supported by AI-driven demand in data centers, but investors should monitor execution on sequential revenue guidance and competitive pressures in the semiconductor space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
